About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Halberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease Antigens

Tau buildup in the brain is linked to Alzheimer's and other neurodegenerative diseases.

JACKSON CENTER, PA / ACCESSWIRE / February 8, 2022 / Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to eliminate 100% of Tau protein from cerebral spinal fluid (CSF) in less than 20 minutes with its patented extracorporeal laser exposure process. Excess Tau in CSF is associated with the onset and progression of Alzheimer's disease and other neurodegenerative diseases. This is the ninth of ten identified neurodegenerative disease target antigens that Halberd has been able to successfully eliminate via its in vitro testing. See Table Below.

The company also completed duplication tests on the elimination of 100% of the cytokine Interleukin-4 (IL-4) as initially reported in preliminary tests in a previous announcement.

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "Tau is one of the known precursors to Alzheimer's disease and several other neurodegenerative diseases. What sets Halberd's approach apart is that other competitive efforts primarily focus on treating the symptoms with ingested or injected drugs - adding things to the body - with their associated potential debilitating side effects and drug interactions."

By contrast, Halberd's methodology removes the pathophysiologic basis (cause) of the disease, extracorporeally, avoiding risks associated with injecting foreign substances into the body as explained in this video."

William A. Hartman, Halberd's Chairman, President & CEO added, "Halberd continues its progress towards eliminating excess neurodegenerative antigens from CSF. Halberd previously demonstrated its capability to selectively eliminate specific target antigens from a mixture of pooled antigens in CSF. Glutamate, an excitatory neurotransmitter, is the only remaining target antigen on our list for controlling neurodegenerative disease states through extracorporeal elimination. I am confident our team is up to this challenge and will be successful in eliminating glutamate as well. We anticipate this will be accomplished shortly, at which time, we will be in a position to present our historical research results to organizations interested in treating PTSD, Chronic Traumatic Encephalopathy (CTE), Alzheimer's disease, ALS, epilepsy, and other neurodegenerative diseases. Our goal is to seek partnerships, endorsements and licensing of our technology development leading to effective treatments."

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation



View source version on accesswire.com:
https://www.accesswire.com/687730/Halberd-Eliminates-100-of-Tau-Protein-From-CSF--The-9th-of-10-Target-Neurodegenerative-Disease-Antigens

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.